THRB (thyroid hormone receptor beta; HGNC:11799, NCBI Gene 7068) is the gene on chromosome 3p24.2 encoding TRbeta — the thyroid-hormone receptor of liver, kidney, and the pituitary (the TSH-feedback receptor and the HPT axis's set-point sensor): the classical resistance-to-thyroid-hormone (RTH-beta) gene and the TRbeta-selective-agonist programs' target.
Approved Symbol
THRB (HGNC:11799)
Chromosomal Locus
3p24.2
Encoded Product
TRbeta — a 50-kDa nuclear receptor (461 aa; the beta1 and beta2 variants)
Primary Pathway
T3 → TRbeta → TRE programs (liver, kidney, pituitary TSH feedback)
Clinical / Therapeutic Role
RTH-beta (Refetoff syndrome); the TRbeta-selective agonist rationale
Gene Structure & Expression
Genomic organization: Ten exons; the beta1 and beta2 variants (beta2 the pituitary-hypothalamic isoform) — the beta tissues' expression file.
Expression: Liver, kidney, and the pituitary/hypothalamic feedback centers — the metabolic and set-point tissues; THRA's brain-heart-bone partition the complement.
RTH-beta depth: Refetoff’s original 1967 family and the subsequent allelic series — the dominant-negative receptor biology (the mutated TRbeta binding TREs without releasing) the textbook’s clearest receptor-dominant-negative case.
Axis depth: The pituitary beta2 isoform’s T3-sensing the set-point — the reason minor T3 changes move TSH logarithmically; the axis’s gain the receptor’s dose-response.
The set-point sensor: TRbeta2 in the pituitary and hypothalamus reading T3 to suppress TSH and TRH — the HPT axis's feedback receptor; the axis's tuning the receptor's occupancy.
Metabolic programs: The liver's T3-responsiveness (the lipid and metabolic genes); the LDL and cholesterol file — the reason thyroid status moves lipids, thyroxine.
Clinical & Therapeutic Significance
Clinical genetics: RTH-beta (Refetoff) — dominantly inherited THRB mutations: high T4/T3 with inappropriately normal TSH, goiter, and the mixed hypo-hyper signature; the allelic series the receptor-biology textbook.
Pharmacology: The TRbeta-selective agonists (sobetirome-lineage; eprotirome's discontinued trial) targeting the liver's lipid program while sparing TRalpha's heart.